GRIDD Study - Update

As of Nov. 10, 2023, we've had participation from 3068 individuals in 94 countries and 95 different disease areas. Psoriasis leads as the condition with the most responses, followed by Lichen Sclerosus and Atopic Eczema. The top countries represented to date are the US, UK and Germany.  

See where which place your country and disease are on these graphs:


What is the GRIDD Study?

On June 5, GlobalSkin in collaboration with Cardiff University (UK) and University Medical Centre Hamburg-Eppendorf (Germany), launched the Global Research on the Impact of Dermatological Diseases (GRIDD) Study.

The GRIDD Study will gather global data about the real impact of conditions of the skin, hair, nails, and mucosa. At the heart of the study is the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure, a tool developed with you and your patients over the past five years to capture and quantify unique patient perspectives.


We have created a toolkit for you to use to help spread the word in your patient communities.  Download the tools here. 

GlobalSkin intends to engage 10,000 patients in the online GRIDD Study which takes approximately 10-20 minutes to complete. Patients may also be asked to complete a follow-up survey six weeks later for validation purposes. The survey is available in 17 languages, including Arabic, Bengali, Chinese (simplified), English, French, Dutch, Danish, German, Hindi, Italian, Japanese, Portuguese, Russian, Serbian, Spanish, Swahili, and Vietnamese.

The GRIDD Study will be open from June 5 to December 31, 2023

The data and insights from the study will support our dermatology patient community's advocacy for improved treatment and accessibility to affordable medicines. Don’t miss out on having your patient community be represented in the in the GRIDD data!

By sharing their experiences through our study, your patients will be helping to show clinicians, researchers, and policymakers the true impact of living with your dermatological condition. The data collected will help to confirm the need for improved care, better treatment options, and more affordable medicine for dermatology patients globally.   
We are excited to also share that the GRIDD Project has been published for a second time in ActaDV Journal. This publication is about Phase 2: A Qualitative Concept Elicitation Study. Please see the link to the paper here.


NEW FEATURE: Register for the GRIDD Study through WhatsApp

To make the GRIDD Study more accessible, we’ve launched a new registration feature! To take the survey, adult dermatology patients can now register at using their WhatsApp number. In doing so, the survey link will be sent directly to that number and participants will be guided straight to the survey. This feature is available in addition to the option of registering through email that has been in place since the beginning of the GRIDD Study.

Why does GRIDD Matter?

The Global Research on the Impact of Dermatological Diseases (GRIDD) project is the first global patient impact project in the history of dermatology. It aims to collect global data on the impact of dermatological diseases directly from patients.

The GRIDD data will support local, national, and international advocacy work for more research, better treatments, and healthcare policies, and, ultimately, will improve the lives of dermatology patients. For the first time, dermatology patients around the world and from all disease types will contribute to a dataset that measures the true impact of living with their diseases.

Why should your patient community participate in the GRIDD Study?

The benefits to your patient organization include: 

  • Your organization will have data insights specifc to your disease area in your region, this will increase your credibility when you take on advocacy activites with policy makers and payers
  • Your organization will have credible data points that can help to raise awareness for your diesease in the media
  • You can increase fundraising by having data to show the impact on your dermatology patient community  

To learn more, please watch the GRIDD presentation on our YouTube Channel. GlobalSkin  hosted a webinar to help explain the psychometric testing in more detail - watch the recording here. 

Together, we will strengthen the voice of patients through data! 


Participants who take the survey will be helping to measure, validate and confirm the very real and difficult challenges faced by dermatology patients.

The data we collect will empower our community with disease impact evidence that will help us advocate for improved care, better treatment options, and more affordable medicines.   

Watch the Patient Testimonial Video to learn Why GRIDD Matters!